Screenshot 2019-10-04 at 16.16.45.png
Screenshot 2019-10-09 at 11.34.57.png

what we do

Ageing Research at King’s (ARK) has developed Europe’s first Longevity AI Consortium in 2019, building upon the foundation it has already established ageing and longevity research to turn scientific innovations into clinical realities. King’s College London is an ideal location for the first Longevity AI Consortium in the UK because it has dedicated divisions and resources both for AI and for Longevity. Furthermore, being located in London, it is in an ideal physical location to engage in cross-sector and industry-academic collaboration.

The Longevity AI Consortium will serve as a leading R&D hub and industry-academic hotspot for advanced AI-driven AI-driven personalized preventive diagnostics, prognostics and therapeutics. The main concept of precision medicine is providing health care which  is individually tailored on the basis of a person’s genes, lifestyle and environment. With the advances in genetics, artificial intelligence and the growing availability of health data, present an opportunity to make precise personalized patient care a clinical reality.

our research

aging analytics agency

1.png

Longevity Industry in UK 

Landscape Overview

ageing research at kings

our Team

dr. richard siow

  • LinkedIn Social Icon

Director at Ageing Research at King's (ARK)

dr. alex zhavoronkov

  • LinkedIn Social Icon

Chief Scientific Officer / 

AI Biomarkers of Ageing

 

our ADVISORS

dmitry kaminskiy

  • LinkedIn Social Icon

Managing Trustee at Biogerontology Research Foundation / Strategic Advisor fo Artificial Intelligence and Commercialisation 

Margaretta Colangelo

  • LinkedIn Social Icon

Co-founder and Managing Partner at Deep Knowledge Ventures and Longevity Capital

Eric kihlstrom

  • LinkedIn Social Icon

Director at Aging Analytics Agency / Former Interim Director of the £98 million Healthy Ageing Industrial Strategy Challenge Fund

contact us

Contact Form
Subscribe to Our News